BioSpace News Archive

Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, will release its first quarter 2021 financial results on Thursday, April 29, 2021, prior to its earnings call at 8:00 a.m. ET.

Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced it has completed the acquisition of Ipsen’s

Implements new corporate strategy to focus on precision therapeutics for the treatment of cancer Strengthens pipeline by acquiring a proprietary portfolio of novel adenosine immuno-modulator compounds Lead asset, RT-AR001, pre-IND filing is on track for the first half of 2021

Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, today announced it will participate in two virtual investor conferences in April 2021 .

IVERIC bio, Inc. reported that on April 1, 2021, the Company granted equity-based awards pursuant to the Company’s 2019 Inducement Stock Incentive Plan to a newly-hired, non-executive employee.

Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that after several months supporting the Padres Front Office’s efforts to reopen safely, Quidel has been chosen as “Official Diagnostics Partner” of the San Diego Padres Major League Baseball (MLB) franchise

Senseonics Holdings, Inc., a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring system for people with diabetes, announced that it had made equity grants to new employees under its 2019 Inducement Plan in accordance with NYSE American Company Guide Section 711.

Arbor Biotechnologies, an early-stage life sciences company unlocking nature’s genetic diversity to enable revolutionary gene editing capabilities, today announced it has appointed Devyn M. Smith, Ph.D., as Chief Executive Officer.

F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation bispecific immunotherapies to transform the lives of patients with cancer, today announces that Ares Trading S.A., an affiliate of Merck KGaA, Darmstadt, Germany has exercised its option to develop an additional bispecific program under the ongoing collaboration with F-star.

Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, announces that its corporate partner HanX Biopharmaceuticals has enrolled three patients in the second dosing cohort of its Phase 1 study with ON 123300 in HR+ HER2- metastatic breast cancer and other advanced relapsed/refractory cancers in China.